Our products are for in vitro research use only, not for clinical diagnosis
-
ProductWe specialize in the development, production and sales of ELISA kits, antibodies, recombinant proteins and related reagents for the international market.
-
ResearchThe company has mature biological technologies such as molecular biology technology, immunology technology, protein expression and purification technology, antibody screening and preparation.
-
ServicesWith excellent products and perfect service system, the company is favored and recognized by the majority of domestic and foreign customers.
-
NewsThe company would like to be your research helper and professional manufacturer.
-
AboutLocated in China Optics Valley Biological City, the company has a modern R&D center and a standard production workshop, and has passed the overall ISO 9001:2022 quality management system certification.
Production and development of vesicle-free cell culture additives for the preparation of human extracellular vesicles
Time：
2023-06-14
Producing vesicle-free cell culture additive for human cells extracellular vesicles manufacturing
Producing vesicle-free cell culture additive for human cells extracellular vesicles manufacturing
Producing vesicle-free cell culture additive for human cells extracellular vesicles manufacturing
The "extracellular vesicle (EV) therapy" method is a promising field in nanomedicine. However, there are still technical limitations to achieve large-scale production of clinical-grade EVs. In this study, we prepared vesicle-free human platelet lysate (hPL) (EV-freehPL) or vesicle-free fetal calf serum FCS (EV-free FCS) additive using tangential flow filtration (TFF), which greatly improved cell viability and cumulative EV yield during EV production, providing a method that can help generate large amounts of EV from almost any mammalian cell. This study provides a method that can be used in the research and development of all kinds of animal sera to generate large amounts of EV from almost any mammalian cell.
11.467
Collaborators Unit.
Université Paris-Saclay, André Léveau
Published in:JournalofControlledRelease
DOI:10.1016/ijconrel.2023.01.073
Product Index & Article Number:CANX Polyclonal Antibody( E-AB-30723)/CANX Polyclonal Antibody( E-A14819)
More Guides
Contact Us
Phone： 400-027-8858
Fax： 027-86627593
Address：A101, Building C1, Bio City, No.666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan
E-mail：reivaa@reivaa.com
Copyright © 2023Wuhan Reivaa Biotech Co., Ltd.
SEO | Business license | IPv6 access support
IPv6 access support
WhatsApp：400-027-8858
Add：A101, Building C1, Bio City, No.666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan
E-mail： mail@reivaa.com
We will give you feedback in time